SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (2718)3/22/2010 12:15:22 PM
From: Jibacoa  Read Replies (1) | Respond to of 3722
 
O.T.

PZZ has +CF and apparently if feels it won't be affected too much by last nite passage of Obamacare.<g>

The stock is up 10.89% although volume remains low at about half its ADV.<g>

bigcharts.marketwatch.com

Bernard



To: Jibacoa who wrote (2718)3/23/2010 8:40:03 AM
From: Biotech Jim  Read Replies (1) | Respond to of 3722
 
It was reported in the news that POZN's Treximet will receive royalties of 18% in 2010, compared to I believe 5% prior to this.

rttnews.com



To: Jibacoa who wrote (2718)3/24/2010 3:12:59 PM
From: Jibacoa  Read Replies (1) | Respond to of 3722
 
POZN was able to go through the resistance at $8

bigcharts.marketwatch.com

The next resistance is now the Oct2008 H at $10.15 <g>

bigcharts.marketwatch.com

The ACTAY is $8.25 but if it can close above $10 it seems the momentum could let it retest the $12 level.<g>

bigcharts.marketwatch.com

Bernard